• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Early Phase Formulation Development Services

Early Phase Formulation Development Services

Our early-phase formulation development services are tailored to address specific drug delivery challenges.

Our early-phase formulation development services help to resolve drug delivery challenges encountered at both preclinical and clinical development stages of small molecules and peptides. We offer specific solutions to your preformulation and formulation needs through customized development strategies and designs.

Our expert team of scientists have successfully delivered projects in wide range of areas like incomplete dissolution, low solubility, low oral bioavailability and targeted drug delivery through in-depth molecular characterization, various solubilization and enabling technologies. At Aurigene, we provide solutions for: Toxicology studies Non-feasibility of high doses or strengths Studies in varied animal species Emesis, compound limitation Liquid dosage form requirement Precipitation of compounds at absorption sites.

Speak to our experts

Our Services for Preclinical Formulation Development

Many hits and lead NCEs get shelved from pharmacological and toxicity screening despite high potency because of poor bioavailability or suboptimal formulation. As a leading CDMO, we have more than a decade of experience in helping our clients to overcome these challenges by enabling GLP toxicology studies.

Our preclinical formulations development approach considers but is not limited to:

  • Administration route (oral, parenteral and topical)
  • Animal species
  • Study duration
  • Excipient tolerability
  • Target exposure
  • Compound properties

NCE properties are assessed from pre-formulation studies suited to the discovery phase to obtain maximum information from minimum compound amounts.

Oral Bioavailability Enhancement Services

Our formulation team has the expertise in troubleshooting complex problems by banking various oral bioavailability strategies to accelerate your drug discovery program to the next phase.

Formulation development strategies are:

Solubilization strategies

  • Micellar solubilization
  • Complexation
  • pH adjustment/buffering
  • Cosolvents

Enabling technologies

  • Solid dispersions
  • Particle size reduction
  • Lipid-based drug delivery systems

Our data-driven approach enables our partners to advance candidates and select the most optimal formulation for a specific drug development phase.

Why Aurigene Pharmaceutical Services?

Services from early formulation to clinical manufacturing

Experience with advanced formulation technologies

Integration with biology services for in vitro and in vivo studies

Global accreditations

Virtual Tour


Contact Us

CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug


Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.